App Update and Rollout to Epassi UK Gym Network

8 December 2025

MedPal AI plc

("MedPal AI" or the "Company")

Major App Update and Rollout to Epassi UK Gym Network

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence ("AI") company focused on health and wellness management, is pleased to announce the release of a major upgrade to its MedPal AI wellness app on both iOS and Android platforms.

Major App Enhancement

The Company has released a significant update to its MedPal AI app (available at iOS App Store or Google Play Store), introducing advanced AI capabilities that represent a substantial evolution in its personalised health management.

The new unified AI assistant allows users to interact via text, voice, or image within a single chat interface covering wellness, fitness, sleep, recovery, and nutrition. The redesigned dashboard features faster loading, updated health metric formulas, and real-time data sync with six-month historical import. An enhanced journal feature now supports AI-powered analysis of uploaded documents and lab results. The update also introduces German language support. Key features include;

·          Test Results Upload: Users can now upload test results directly into the app, enabling the AI to provide more comprehensive and contextualised health insights;

·          Portable Health Records: Wherever you are, you will have all of your test results and documents stored with you on your MedPal app;

·          AI Memory Function: The app now builds a continuous memory of each user's health journey, enabling increasingly personalised recommendations based on historical patterns and trends; and

·          Enhanced Personalisation: The AI system learns from user data over time, delivering wellness guidance that becomes increasingly accurate and tailored to individual needs.

This update significantly enhances the app's value proposition by transforming it from a real-time health data aggregator into an intelligent, longitudinal health companion that monitors each user's unique health trajectory.

Epassi Partnership Deployment

The updated app is now being rolled out across networks of UK gyms under the Company's partnership agreement with Epassi UK Limited. This partnership provides access to 11 million+ employees at major firms including Siemens and Volvo, representing a significant distribution channel for the enhanced app capabilities.

The timing of this major release with the Epassi rollout positions MedPal AI to capture substantial user engagement across the corporate wellness sector, offering free 12-month access to Epassi's 11 million+ users as part of employee wellness benefits. Subscription options for premium features are available at £3.99 monthly or £29.99 annually.

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

"This major app update represents a significant leap forward in our AI capabilities. The ability to upload test results and have our AI build a comprehensive memory of each user's health profile creates a truly personalised wellness experience that goes beyond simple activity tracking.

"The rollout to UK gyms through our Epassi partnership provides immediate access to millions of potential users who will benefit from these advanced features. This positions MedPal AI at the forefront of AI-powered preventive healthcare, combining our existing strength in wearable data aggregation with deeper insights from test results and longitudinal health patterns.

"We continue to enhance our dual-engine model, where our wellness app drives user engagement and awareness, whilst MedPal.clinic provides the pharmacy and clinical fulfilment. This latest update strengthens that flywheel significantly."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Enquiries:

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.